Antharis Therapeutics, Inc.

Antharis Therapeutics is a multinational biopharmaceutical company developing new treatments for cancer and inflammatory diseases. In particular, our company utilizes cutting-edge science to develop next-generation therapeutic monoclonal antibodies and antibody-drug conjugates with the end goal of treating unmet medical needs. The company, founded by Dr. Raphael R Pinaud in 2020, has significantly grown and successfully advanced its mission to date. Furthermore, Antharis strategically acquired Cassyni Biopharma and Galileo Biotech, in mid-2022 and mid-2023, respectively, to further and more effectively advance its mandate to bring transformational therapies to patients in need. Antharis has built an extensive pipeline of innovative therapies and, through pioneering research, is poised to initiate clinical trials in 2025 with several of its assets, making significant strides toward addressing unmet oncology needs.